• Something wrong with this record ?

Antiviral activities of 2,6-diaminopurine-based acyclic nucleoside phosphonates against herpesviruses: In vitro study results with pseudorabies virus (PrV, SuHV-1)

D. Zouharova, I. Lipenska, M. Fojtikova, P. Kulich, J. Neca, M. Slany, K. Kovarcik, P. Turanek-Knotigova, F. Hubatka, H. Celechovska, J. Masek, S. Koudelka, L. Prochazka, L. Eyer, J. Plockova, E. Bartheldyova, AD. Miller, D. Ruzek, M. Raska, Z....

. 2016 ; 184 (-) : 84-93. [pub] 20160118

Language English Country Netherlands

Document type Journal Article, Research Support, Non-U.S. Gov't

Pseudorabies virus (PrV), a causative agent of Aujeszky's disease, is deadly to most mammals with the exception of higher primates and men. This disease causes serious economic loses among farm animals, especially pigs, yet many European countries are today claimed to be Aujeszky's disease free because of the discovery of an efficient vaccination for pigs. In reality, the virus is still present in wild boar. Current vaccines are neither suitable for dogs nor are there anti-PrV drugs approved for veterinary use. Therefore, the disease still represents a high threat, particularly for expensive hunting dogs that can come into close contact with infected boars. Here we report on the anti-PrV activities of a series of synthetic diaminopurine-based acyclic nucleoside phosphonate (DAP-ANP) analogues. Initially, all synthetic DAP-ANPs under investigation are shown to exhibit minimal cytotoxicity by MTT and XTT tests (1-100μM range). Thereafter in vitro infection models are established using PrV virus SuHV-1, optimized on PK-15 and RK-13 cell lines. Out of the six DAP-ANP analogues tested, analogue VI functionalized with a cyclopropyl group on the 6-amino position of the purine ring proves the most effective antiviral DAP-ANP analogue against PrV infection, aided by sufficient hydrophobic character to enhance bioavailability to its cellular target viral DNA-polymerase. Four other DAP-ANP analogues with functional groups introduced to the C2'position are shown ineffective against PrV infection, even with favourable hydrophobic properties. Cidofovir(®), a drug approved against various herpesvirus infections, is found to exert only low activity against PrV in these same in vitro models.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000510
003      
CZ-PrNML
005      
20230808135839.0
007      
ta
008      
170103s2016 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.vetmic.2016.01.010 $2 doi
024    7_
$a 10.1016/j.vetmic.2016.01.010 $2 doi
035    __
$a (PubMed)26854349
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Zouharova, Darina $u Veterinary Research Institute, Department of Pharmacology and Immunotherapy, Brno, Czech Republic.
245    10
$a Antiviral activities of 2,6-diaminopurine-based acyclic nucleoside phosphonates against herpesviruses: In vitro study results with pseudorabies virus (PrV, SuHV-1) / $c D. Zouharova, I. Lipenska, M. Fojtikova, P. Kulich, J. Neca, M. Slany, K. Kovarcik, P. Turanek-Knotigova, F. Hubatka, H. Celechovska, J. Masek, S. Koudelka, L. Prochazka, L. Eyer, J. Plockova, E. Bartheldyova, AD. Miller, D. Ruzek, M. Raska, Z. Janeba, J. Turanek,
520    9_
$a Pseudorabies virus (PrV), a causative agent of Aujeszky's disease, is deadly to most mammals with the exception of higher primates and men. This disease causes serious economic loses among farm animals, especially pigs, yet many European countries are today claimed to be Aujeszky's disease free because of the discovery of an efficient vaccination for pigs. In reality, the virus is still present in wild boar. Current vaccines are neither suitable for dogs nor are there anti-PrV drugs approved for veterinary use. Therefore, the disease still represents a high threat, particularly for expensive hunting dogs that can come into close contact with infected boars. Here we report on the anti-PrV activities of a series of synthetic diaminopurine-based acyclic nucleoside phosphonate (DAP-ANP) analogues. Initially, all synthetic DAP-ANPs under investigation are shown to exhibit minimal cytotoxicity by MTT and XTT tests (1-100μM range). Thereafter in vitro infection models are established using PrV virus SuHV-1, optimized on PK-15 and RK-13 cell lines. Out of the six DAP-ANP analogues tested, analogue VI functionalized with a cyclopropyl group on the 6-amino position of the purine ring proves the most effective antiviral DAP-ANP analogue against PrV infection, aided by sufficient hydrophobic character to enhance bioavailability to its cellular target viral DNA-polymerase. Four other DAP-ANP analogues with functional groups introduced to the C2'position are shown ineffective against PrV infection, even with favourable hydrophobic properties. Cidofovir(®), a drug approved against various herpesvirus infections, is found to exert only low activity against PrV in these same in vitro models.
650    _2
$a 2-aminopurin $x analogy a deriváty $x chemie $x farmakologie $7 D015075
650    _2
$a zvířata $7 D000818
650    _2
$a antivirové látky $x chemie $x farmakologie $7 D000998
650    _2
$a buněčné linie $7 D002460
650    _2
$a replikace DNA $x účinky léků $7 D004261
650    _2
$a psi $7 D004285
650    _2
$a Herpesviridae $x účinky léků $7 D006564
650    _2
$a techniky in vitro $7 D066298
650    _2
$a buňky MDCK $7 D061985
650    _2
$a transmisní elektronová mikroskopie $7 D046529
650    _2
$a organofosfonáty $x chemie $x farmakologie $7 D063065
650    _2
$a pseudovzteklina $x farmakoterapie $7 D011557
650    _2
$a Vero buňky $7 D014709
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Lipenska, Ivana $u Veterinary Research Institute, Department of Pharmacology and Immunotherapy, Brno, Czech Republic.
700    1_
$a Fojtikova, Martina $u Veterinary Research Institute, Department of Pharmacology and Immunotherapy, Brno, Czech Republic.
700    1_
$a Kulich, Pavel $u Veterinary Research Institute, Department of Pharmacology and Immunotherapy, Brno, Czech Republic.
700    1_
$a Neca, Jiri $u Veterinary Research Institute, Department of Pharmacology and Immunotherapy, Brno, Czech Republic.
700    1_
$a Slany, Michal $u Veterinary Research Institute, Department of Pharmacology and Immunotherapy, Brno, Czech Republic.
700    1_
$a Kovarcik, Kamil $u Veterinary Research Institute, Department of Pharmacology and Immunotherapy, Brno, Czech Republic.
700    1_
$a Turánek-Knötigová, Pavlína $u Veterinary Research Institute, Department of Pharmacology and Immunotherapy, Brno, Czech Republic. $7 xx0137875
700    1_
$a Hubatka, Frantisek $u Veterinary Research Institute, Department of Pharmacology and Immunotherapy, Brno, Czech Republic.
700    1_
$a Celechovska, Hana $u Veterinary Research Institute, Department of Pharmacology and Immunotherapy, Brno, Czech Republic.
700    1_
$a Masek, Josef $u Veterinary Research Institute, Department of Pharmacology and Immunotherapy, Brno, Czech Republic.
700    1_
$a Koudelka, Stepan $u Veterinary Research Institute, Department of Pharmacology and Immunotherapy, Brno, Czech Republic; International Clinical Research Center, St. Annés University Hospital, Brno, Czech Republic.
700    1_
$a Prochazka, Lubomir $u Veterinary Research Institute, Department of Pharmacology and Immunotherapy, Brno, Czech Republic.
700    1_
$a Eyer, Luděk $u Veterinary Research Institute, Department of Pharmacology and Immunotherapy, Brno, Czech Republic. $7 xx0098551
700    1_
$a Plockova, Jana $u Veterinary Research Institute, Department of Pharmacology and Immunotherapy, Brno, Czech Republic.
700    1_
$a Bartheldyova, Eliska $u Veterinary Research Institute, Department of Pharmacology and Immunotherapy, Brno, Czech Republic.
700    1_
$a Miller, Andrew D $u King's College London, Institute of Pharmaceutical Science, London, United Kingdom, and GlobalAcorn Ltd., London, United Kingdom.
700    1_
$a Růžek, Daniel, $u Veterinary Research Institute, Department of Pharmacology and Immunotherapy, Brno, Czech Republic; Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, and Faculty of Science, University of South Bohemia, Ceske Budejovice, Czech Republic. $d 1981- $7 stk2008441707
700    1_
$a Raska, Milan $u Veterinary Research Institute, Department of Pharmacology and Immunotherapy, Brno, Czech Republic; Palacky University of Olomouc, Faculty of Medicine, Department of Immunology, Czech Republic.
700    1_
$a Janeba, Zlatko $u Institute of Organic Chemistry and Biochemistry, The Czech Academy of Sciences, Prague, Czech Republic.
700    1_
$a Turanek, Jaroslav $u Veterinary Research Institute, Department of Pharmacology and Immunotherapy, Brno, Czech Republic. Electronic address: turanek@vri.cz.
773    0_
$w MED00005709 $t Veterinary microbiology $x 1873-2542 $g Roč. 184, č. - (2016), s. 84-93
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26854349 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20230808135836 $b ABA008
999    __
$a ok $b bmc $g 1179650 $s 961077
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 184 $c - $d 84-93 $e 20160118 $i 1873-2542 $m Veterinary microbiology $n Vet Microbiol $x MED00005709
LZP    __
$a Pubmed-20170103

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...